Eli Lilly And Co (NYSE:LLY) Shares Sold by Shufro Rose & Co. LLC

Shufro Rose & Co. LLC reduced its stake in Eli Lilly And Co (NYSE:LLY) by 0.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 46,814 shares of the company’s stock after selling 155 shares during the period. Shufro Rose & Co. LLC’s holdings in Eli Lilly And Co were worth $6,075,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Athena Capital Advisors LLC acquired a new position in Eli Lilly And Co during the 4th quarter worth approximately $26,000. Wakefield Asset Management LLLP purchased a new stake in Eli Lilly And Co during the 4th quarter worth approximately $27,000. Larson Financial Group LLC purchased a new stake in Eli Lilly And Co during the 4th quarter worth approximately $29,000. Trust Department MB Financial Bank N A increased its holdings in Eli Lilly And Co by 54.7% during the 1st quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after purchasing an additional 82 shares during the last quarter. Finally, Acima Private Wealth LLC bought a new stake in shares of Eli Lilly And Co in the 4th quarter valued at approximately $33,000. 79.42% of the stock is owned by hedge funds and other institutional investors.

LLY traded down $0.08 during mid-day trading on Friday, reaching $111.74. The stock had a trading volume of 3,188,050 shares, compared to its average volume of 11,432,627. Eli Lilly And Co has a 52 week low of $84.64 and a 52 week high of $132.13. The company has a debt-to-equity ratio of 5.50, a quick ratio of 0.85 and a current ratio of 1.12. The firm has a market capitalization of $111.88 billion, a price-to-earnings ratio of 20.13, a PEG ratio of 2.04 and a beta of 0.27.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.01. The business had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.12 billion. Eli Lilly And Co had a return on equity of 56.62% and a net margin of 26.13%. The firm’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $1.31 EPS. As a group, research analysts forecast that Eli Lilly And Co will post 5.66 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, June 10th. Shareholders of record on Friday, May 17th were paid a $0.645 dividend. This represents a $2.58 annualized dividend and a dividend yield of 2.31%. The ex-dividend date of this dividend was Thursday, May 16th. Eli Lilly And Co’s dividend payout ratio is 46.49%.

A number of research analysts have issued reports on the company. Goldman Sachs Group assumed coverage on Eli Lilly And Co in a research report on Tuesday, May 28th. They set a “buy” rating and a $135.00 price target for the company. Zacks Investment Research lowered Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. TheStreet lowered Eli Lilly And Co from a “b+” rating to a “c+” rating in a report on Thursday, May 9th. BMO Capital Markets upped their price objective on Eli Lilly And Co from $130.00 to $133.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $143.00 price target on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Ten research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $119.99.

In other Eli Lilly And Co news, VP Michael J. Harrington sold 16,000 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the transaction, the vice president now owns 110,300 shares of the company’s stock, valued at $12,874,216. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Aarti S. Shah sold 1,800 shares of the business’s stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $125.85, for a total value of $226,530.00. Following the transaction, the senior vice president now directly owns 18,425 shares in the company, valued at approximately $2,318,786.25. The disclosure for this sale can be found here. Insiders sold a total of 246,112 shares of company stock worth $31,888,255 in the last three months. Company insiders own 0.11% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by Rockland Register and is owned by of Rockland Register. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://rocklandregister.com/2019/06/14/eli-lilly-and-co-lly-holdings-reduced-by-shufro-rose-co-llc.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Average Daily Trade Volume – ADTV

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.